ERX-315 CLINICAL TRIAL APPROVED BY HREC

Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled “A Phase 1 Trial of ERX-315 in Participants with Advanced Solid Tumors”

The trial will begin to recruit patients at The Kinghorn Cancer Centre in Sydney and be overseen by the overall trial principal investigator, Dr. Rasha Cosman, the Head of Early Phase Clinical Trials Unit and the Clinical Lead of Oncology Clinical Trials at the Kinghorn Cancer Center.  The trial will evaluate the safety and tolerability of ERX-315 in in patients with advanced solid tumors, who have progressed on prior approved systemic therapies.

ERX-315 is designed to target specific pathways that are critical for cancer cell survival and proliferation. This targeted approach helps to spare healthy cells, potentially reducing side effects commonly associated with cancer therapies.

Interested individuals can learn more about the trial, eligibility criteria, and how to participate by visiting the link here:  ERX-315 Clinical Trial.

Etira will provide updates on the continued progress of the ERX-315 clinical trial and activation in additional clinical trial sites in Australia. This clinical trial represents a significant step forward in Etira’s pursuit of effective treatments for patients with metastatic therapy-resistant cancers.